Issue 73, 2022

Chiral gold(iii) complexes: speciation, in vitro, and in vivo anticancer profile

Abstract

Emerging synthetic development of chiral gold(III) complexes has prompted new opportunities in catalysis and material science with limited utility in biomedicine. Here, we demonstrate potential chemotherapeutic capability of [C^N]Au(III)Cl(R-DuPhos) (1–7) complexes, containing 1,2-bis[(2R,5R)-2,5-dialkylphospholano]benzene, which shows good stabilty, potent anticancer activity, and tolerability in mice.

Graphical abstract: Chiral gold(iii) complexes: speciation, in vitro, and in vivo anticancer profile

Supplementary files

Article information

Article type
Communication
Submitted
31 May 2022
Accepted
12 Aug 2022
First published
16 Aug 2022

Chem. Commun., 2022,58, 10237-10240

Author version available

Chiral gold(III) complexes: speciation, in vitro, and in vivo anticancer profile

A. S. Arojojoye, J. H. Kim, C. Olelewe, S. Parkin and S. G. Awuah, Chem. Commun., 2022, 58, 10237 DOI: 10.1039/D2CC03081K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements